ZTS
Zoetis·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 6
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
Revenue Beats Expectation
Low Beta
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ZTS
Zoetis Inc.
A world's leading animal health medicines and vaccines developer with a focus on livestock and companion animals
10 Sylvan Way, Parsippany, New Jersey 07054
Production and development of pet health drug products and vaccines
Zoetis, Inc. was founded in July 2012 in Delaware, USA. Zoetis is a global leader in the animal health industry, focusing on the discovery, development, manufacturing and commercialization of drugs, vaccines, diagnostic products and services, biological devices, genetic testing and precision animal health.
Earnings Call
Q1/2025
Estimate EPS1.4
Actual EPS1.48
Estimate Revenue2.19B
Actual Revenue2.22B
Contradictions Unveiled: Analyzing Market Strategies and Growth Projections from the Latest Librela Earnings Call
May 06,2025 07:34
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS1.61
Actual EPS1.76
Estimate Revenue2.41B
Actual Revenue2.46B
Zoetis Q2 2025: Navigating Contradictions in Librella Growth, Tariffs, and Market Competition
Aug 05,2025 12:31
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS1.65
Actual EPS1.7
Estimate Revenue2.42B
Actual Revenue2.40B
Zoetis's Q3 2025: Contradictions Emerge on Librela Recovery, U.S. Market Dynamics, Dermatology, and 2026 Growth Outlook
Nov 04,2025 11:14
Earnings Decrypt
Earnings Decrypt
Q4/2025
Estimate EPS--
Actual EPS--
Estimate Revenue2.42B
Actual Revenue--
Phibro's Q4 2025 Earnings Call: Contradictions in MFA Growth, Zoetis Integration, Tariff Impact, and Inventory Strategy Revealed
Aug 28,2025 11:19
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ZTS has released its 2025 Q3 earnings. EPS was reported at 1.7, versus the expected 1.65, beating expectations. The chart below visualizes how ZTS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ZTS has released its 2025 Q3 earnings report, with revenue of 2.40B, reflecting a YoY change of 0.50%, and net profit of 721.00M, showing a YoY change of 4.19%. The Sankey diagram below clearly presents ZTS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
